共 72 条
[1]
Grunberg SM(2004)Incidence of chemotherapy-induced nausea and emesis after modern antiemetics Cancer 100 2261-2268
[2]
Deuson RR(1998)Initial control of chemotherapy-induced nausea and vomiting in patient quality of life Oncology (Williston Park) 12 32-37
[3]
Mavros P(2007)Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings Support Care Cancer 15 497-503
[4]
Geling O(2005)Emesis induced by low or minimal emetic risk chemotherapy Support Care Cancer 13 109-111
[5]
Hansen M(2011)Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC) Curr Med Res Opin 27 837-845
[6]
Cruciani G(2009)Palonosetron: in the prevention of nausea and vomiting Drugs 69 2257-2278
[7]
Morrow GR(2004)Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects J Clin Pharmacol 44 520-531
[8]
Roscoe JA(2010)Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function Eur J Pharmacol 626 193-199
[9]
Hickok JT(2003)Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann Oncol 14 1570-1577
[10]
Stern RM(2003)Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT Cancer 98 2473-2482